Ernexa Therapeutics Inc. (ERNA) vs PharmaCyte Biotech, Inc. (PMCB)
A side-by-side comparison of Ernexa Therapeutics Inc. and PharmaCyte Biotech, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ERNA
Ernexa Therapeutics Inc.
$2.46HealthcareDelayed quote: Oct 6, 2026, 1:19 PM EDT
PMCB
PharmaCyte Biotech, Inc.
$0.43HealthcareDelayed quote: Oct 6, 2026, 1:14 PM EDT
Total return — ERNA vs PMCB
growth of $100 · dividends reinvested · last 10yERNA -100.0% (-65.1%/yr)PMCB -99.4% (-39.7%/yr)PMCB compounded faster over this window
Log scale — wide-divergence pair
ERNA PMCB
ERNA vs PMCB: by the numbers
- •PMCB is the larger company ($5M vs $4M market cap).
Metrics side by side
Valuation
| Metric | ERNA | PMCB |
|---|---|---|
| P/B ratio | 1.25 | 0.16 |
Profitability
| Metric | ERNA | PMCB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -383.03% | -54.15% |
| ROIC | -346.94% | -19.51% |
Growth (annualized)
| Metric | ERNA | PMCB |
|---|---|---|
| Total return CAGR (5Y) | -86.83% | -33.59% |
Frequently asked
- How have ERNA and PMCB total returns compared?
- Over the past 10 years, ERNA delivered -65.14% and PMCB delivered -39.91% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.